

Press Release

Notice Regarding Change in fair value of contingent consideration and Differences Between Consolidated Financial Forecasts and Actual Results for the Fiscal Year Ended March 31, 2025

TOKYO, April 25, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it booked Change in fair value of contingent consideration as other income in the fourth quarter of fiscal year ended March 31, 2025 and that there are differences between the financial forecasts (Full basis), which were reported on January 24, 2025, and the actual results for the fiscal year 2024.

1. Booking and details of change in fair value of contingent consideration

- Due to updates to the clinical development plan for zolbetuximab for pancreatic adenocarcinoma, Astellas booked ¥8.0 billion in changes in the fair value of the contingent consideration as other income.
- Due to the discontinuation of programs related to Xyphos Biosciences, Inc., Astellas booked ¥7.6 billion in changes in the fair value of the contingent consideration as other income.

2. The Differences Between Financial Forecasts (announced on January 24, 2025) and Actual results for the Fiscal Year Ended March 31, 2025 (Full basis)

Operating profit and other line items (Full basis) were higher than the forecasts due to such matters as Change in fair value of contingent consideration as discussed above.

< Full basis >

(Millions of yen)

	Revenue	Operating profit	Profit before tax	Profit for the year	Profit attributable to owners of the parent
Previous forecast (A)	1,900,000	11,000	1,000	14,000	14,000
Actual results (B)	1,912,323	41,039	31,237	50,747	50,747
Change (B-A)	12,323	30,039	30,237	36,747	36,747
Change (%)	0.6	273.1	-	262.5	262.5
(Ref.) Actual fiscal year 2023	1,603,672	25,518	24,969	17,045	17,045

The above is reflected in the financial results of Astellas for FY2024 which were announced today.

About Astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes

In this press release, statements made concerning current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs considering the information currently available to it and involve known and unknown risks and uncertainties. Several factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201